Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell-cytotoxic T lymphocyte + autologous tumor-infiltrating lymphocyte
- Development stage
- Unknown
- Lead developer
- Shenzhen Second People’s Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is a combination immunotherapy involving two types of autologous cell products: dendritic cell-activated cytotoxic T lymphocytes (DC-CTL) and tumor-infiltrating lymphocytes (TIL). Dendritic cells are harvested from the patient, loaded with tumor antigens, and used to prime and expand cytotoxic T lymphocytes ex vivo. Simultaneously, TILs are isolated from the patient's tumor tissue and expanded to large numbers. The combination of these two cell populations is then re-infused into the patient, aiming to provide a synergistic anti-tumor effect by combining the antigen-specific priming of DC-CTLs with the broad, tumor-resident repertoire of TILs. This approach is currently being investigated by Shenzhen Second People's Hospital for the treatment of advanced breast cancer.
- Other names
- DC-CTL + TILautologous TILs and DC-CTLsautologous dendritic cell-activated cytotoxic T lymphocyte + autologous tumor-infiltrating lymphocyte
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on autologous dendritic cell-cytotoxic T lymphocyte + autologous tumor-infiltrating lymphocyte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell-cytotoxic T lymphocyte + autologous tumor-infiltrating lymphocyte.